Skip to main content
Premium Trial:

Request an Annual Quote

RXi Data Shows Anti-Scarring Drug Active in Non-human Primate Eyes


NEW YORK (GenomeWeb) – RXi Pharmaceuticals last week announced positive preclinical data from a program exploring the use of its anti-scarring drug candidate RXI-109 in ophthalmic conditions, showing that intravitreal injection of the agent cut levels of its target protein in the eyes of non-human primates.

RXI-109 comprises siRNAs designed to inhibit connective tissue growth factor, or CTGF, a protein linked to wound healing and other fibrotic processes. It employs the company's proprietary self-delivering technology, which enables cellular uptake without the need for a delivery vehicle.

Although the drug is already in the clinic as treatment for dermal scarring — RXi last year kicked off a Phase II trial in patients with hypertrophic scars and recently began another in patients undergoing keloid removal — it is also under evaluation for use in preventing retinal and corneal scarring.

To that end, RXi conducted a dose range-finding study in cynomolgus monkeys. After the animals received intravitreal injections of RXI-109, whole eye sections were collected and analyzed, showing dose-dependent reductions of CTGF in both the retinas and corneas.

"This finding opens up an avenue to possibly develop topical forms of RXI-109 to combat corneal scarring which often occurs secondary to trauma or infection and can lead to visual impairment, including blindness," RXi President and CEO Geert Cauwenbergh said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.